Book a Meeting

Anti-LTA Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP521) (CAT#: AES-0622-ZP521) Datasheet

Target
LTA
Description
Anti-LTA FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced LTA antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
Pateclizumab; 1202526-59-7; Anti-LTa; RG7416; MLTA3698A; PRO283698; LTA; lymphotoxin alpha (TNF superfamily; member 1); TNFB; lymphotoxin-alpha; LT; TNFSF1; LT-alpha; TNF-beta; tumor necrosis factor beta; tumor necrosis factor ligand superfamily member 1;
Antibody Clone
AES-0622-ZP521
Description
Anti-LTA FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.